ATE529105T1 - Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankung - Google Patents

Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankung

Info

Publication number: ATE529105T1
Authority: AT; Austria
Prior art keywords: lipoic acid; inflammatory bowel; compositions; subject invention; administration
Prior art date: 2007-06-13

Application number

AT08768441T

Other languages

English (en)

Inventor

Jay Pravda

Original Assignee

Jay Pravda

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-13

Filing date

2008-06-13

Publication date

2011-11-15

2008-06-13 Application filed by Jay Pravda filed Critical Jay Pravda

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE529105T1 publication Critical patent/ATE529105T1/de

Links

239000000203 mixture Substances 0.000 title abstract 9
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 title abstract 7
208000022559 Inflammatory bowel disease Diseases 0.000 title abstract 2
235000019136 lipoic acid Nutrition 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
229960002663 thioctic acid Drugs 0.000 abstract 3
206010009900 Colitis ulcerative Diseases 0.000 abstract 2
241000792859 Enema Species 0.000 abstract 2
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 2
201000006704 Ulcerative Colitis Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000007920 enema Substances 0.000 abstract 2
229940095399 enema Drugs 0.000 abstract 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
230000036542 oxidative stress Effects 0.000 abstract 2
IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 abstract 1
AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 abstract 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
208000011231 Crohn disease Diseases 0.000 abstract 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
229930182816 L-glutamine Natural products 0.000 abstract 1
229960004436 budesonide Drugs 0.000 abstract 1
230000001010 compromised effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
229960000890 hydrocortisone Drugs 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 abstract 1
229960004963 mesalazine Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Dental Preparations (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

AT08768441T 2007-06-13 2008-06-13 Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankung ATE529105T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US93450507P	2007-06-13	2007-06-13
US6374508P	2008-02-06	2008-02-06
PCT/US2008/007401 WO2008156671A2 (en)	2007-06-13	2008-06-13	Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Publications (1)

Publication Number	Publication Date
ATE529105T1 true ATE529105T1 (de)	2011-11-15

Family

ID=40156844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08768441T ATE529105T1 (de)	2007-06-13	2008-06-13	Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankung

Country Status (14)

Country	Link
US (2)	US8476233B2 (de)
EP (2)	EP2162125B1 (de)
JP (1)	JP2010529197A (de)
KR (1)	KR20100038098A (de)
CN (1)	CN101707877B (de)
AT (1)	ATE529105T1 (de)
AU (1)	AU2008266996A1 (de)
BR (1)	BRPI0812729A2 (de)
CA (1)	CA2691132C (de)
IL (1)	IL202685A0 (de)
MX (1)	MX2009013683A (de)
NZ (1)	NZ581710A (de)
WO (1)	WO2008156671A2 (de)
ZA (1)	ZA200908828B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8916546B2 (en)	2003-08-29	2014-12-23	Therapeutic Research Llc	Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US20100112088A1 (en) *	2003-08-29	2010-05-06	Jay Pravda	Materials and methods for treatment of disorders associated with oxidative stress
BR112014020095A8 (pt) *	2012-02-13	2017-07-11	Cosmo Tech Limited	Método para tratar doenças intestinais apresentando pelo menos um componente inflamatório
JP6566638B2 (ja) *	2012-03-07	2019-08-28	サンタラス，インコーポレイテッドＳａｎｔａｒｕｓ，Ｉｎｃ．	メサラミンの放出制御固形製剤
JP6509112B2 (ja) *	2012-07-03	2019-05-08	プラブダ，ジェイ	オキソ関連状態の治療、診断および／またはその進行のモニタリングのための方法
WO2014074995A1 (en) *	2012-11-09	2014-05-15	Scidose, Llc	Enema composition for treatment of ulcerative colitis having long term stability
CN103622974B (zh) *	2013-12-05	2016-04-20	武汉武药科技有限公司	一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
WO2016121147A1 (ja)	2015-01-26	2016-08-04	Ｅａファーマ株式会社	注腸剤
ES2688119T3 (es) *	2015-07-08	2018-10-31	Dr. Falk Pharma Gmbh	Formulación farmacéutica para el tratamiento de cambios inflamatorios del recto
US20180353447A1 (en) *	2015-11-27	2018-12-13	Birrbeheer B.V.	Butyrate salts for use in inflammatory diseases
CA3038488A1 (en) *	2016-09-26	2018-03-29	Precision Medicine Holdings Pty Ltd	Diagnosis, prognosis and treatment for schizophrenia and schizoaffective psychosis
WO2018122086A1 (en) *	2016-12-28	2018-07-05	Dr. Falk Pharma Gmbh	Enema for rectal application
CN108034631A (zh) *	2017-12-04	2018-05-15	武汉轻工大学	一种双氧水诱导猪小肠上皮细胞凋亡模型的建立方法
JP2019113375A (ja) *	2017-12-22	2019-07-11	サッポロホールディングス株式会社	腸内環境評価方法、大腸炎罹患リスク評価方法、及び腸内環境改善物質のスクリーニング方法
CN111867583B (zh) *	2018-01-18	2024-07-12	学校法人庆应义塾	治疗溃疡性大肠炎的胶囊剂
GB201906917D0 (en) *	2019-05-16	2019-07-03	Intract Pharma Ltd	Novel compositions
CA3263395A1 (en) *	2022-07-27	2024-02-01	Redox Bioscience LLC	METHODS AND COMPOUNDS FOR THE TREATMENT OF ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, SEPSIS AND POST-SEPSIS SYNDROME
JP2025066445A (ja) *	2023-10-11	2025-04-23	国立大学法人東北大学	炎症性疾患の治療薬、及び治療薬のスクリーニング方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4211777A (en) *	1977-11-25	1980-07-08	Fisons Limited	Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
WO1981002671A1 (en)	1980-03-20	1981-10-01	Ferring Farma Lab	Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4657900A (en)	1983-09-27	1987-04-14	Rowell Laboratories	Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
EP0382066A3 (de)	1989-02-09	1992-01-08	ASTA Medica Aktiengesellschaft	Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
GB8909559D0 (en)	1989-04-26	1989-06-14	Smith Kline French Lab	Pharmaceutical compositions
US5378470A (en)	1989-07-25	1995-01-03	Henning Berlin Gmbh	Rectally administered pharmaceutical preparation
ES2115589T3 (es)	1989-11-09	1998-07-01	Asta Medica Ag	Medicamento que contiene acido r-alfa-liponico o acido s-alfa-liponico como sustancia activa.
US5569670A (en)	1992-06-05	1996-10-29	Asta Medica Aktiengesellschaft	Combination medications containing alpha-lipoic acid and related
DE4218572A1 (de)	1992-06-05	1993-12-09	Asta Medica Ag	Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US8178516B2 (en)	1992-06-30	2012-05-15	Sylvan Labs, LLC	Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en)	1992-06-30	2002-09-03	Howard K. Shapiro	Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en)	1992-06-30	2005-04-28	Shapiro Howard K.	Compositions and method for treatment of chronic inflammatory diseases
JP2917799B2 (ja)	1994-03-11	1999-07-12	田辺製薬株式会社	消化管内適所放出型製剤
US5563131A (en)	1994-08-04	1996-10-08	Pherin Corporation	Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
DE19509806A1 (de)	1995-03-21	1996-09-26	Basf Ag	Lagerstabile Arzneiformen
US5817630A (en)	1997-03-18	1998-10-06	Austin Nutriceutical Corporation	Glutathione antioxidant eye drops
US6197749B1 (en)	1997-10-29	2001-03-06	Ajinomoto Co., Inc.	Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
WO1999055326A1 (en)	1998-04-30	1999-11-04	Vit-Immune, L.C.	Method of treatment of glutathione deficient mammals
CA2274943A1 (en) *	1998-06-17	1999-12-17	Stephen L. Wolman	Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
AR042572A1 (es)	1999-04-02	2005-06-29	Sod Conseils Rech Applic	Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
US6664287B2 (en)	2000-03-15	2003-12-16	Bethesda Pharmaceuticals, Inc.	Antioxidants
EP1172110A3 (de)	2000-07-07	2003-09-17	Basf Aktiengesellschaft	Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
BR0209474A (pt) *	2001-05-09	2006-02-07	Novartis Ag	Métodos para imunomodulação seletiva
US20030235571A1 (en)	2002-06-19	2003-12-25	Gabriel Gojon-Romanillos	Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
CA2498581C (en)	2002-09-10	2019-03-19	National Jewish Medical And Research Center	Thioredoxin composition and uses thereof for liquefaction of mucus or sputum
US7157444B2 (en)	2002-12-21	2007-01-02	Deanna Jean Nelson	Aminosalicylate derivatives for treatment of inflammatory bowel disease
DE10305661A1 (de)	2003-02-12	2004-08-26	Degussa Ag	Darreichungsform zur Kolon-spezifischen Wirkstofffreisetzung
US20060264408A1 (en) *	2003-03-06	2006-11-23	Haj-Yehia Abdullah I	Sod minic multifunctional compounds for treating inflammatory bowel disease
US20100112088A1 (en)	2003-08-29	2010-05-06	Jay Pravda	Materials and methods for treatment of disorders associated with oxidative stress

2008
- 2008-06-13 AT AT08768441T patent/ATE529105T1/de not_active IP Right Cessation
- 2008-06-13 BR BRPI0812729-8A patent/BRPI0812729A2/pt not_active IP Right Cessation
- 2008-06-13 MX MX2009013683A patent/MX2009013683A/es active IP Right Grant
- 2008-06-13 WO PCT/US2008/007401 patent/WO2008156671A2/en not_active Ceased
- 2008-06-13 NZ NZ581710A patent/NZ581710A/en not_active IP Right Cessation
- 2008-06-13 EP EP08768441A patent/EP2162125B1/de not_active Not-in-force
- 2008-06-13 CA CA2691132A patent/CA2691132C/en not_active Expired - Fee Related
- 2008-06-13 AU AU2008266996A patent/AU2008266996A1/en not_active Abandoned
- 2008-06-13 EP EP11179459A patent/EP2392321A1/de not_active Withdrawn
- 2008-06-13 US US12/664,237 patent/US8476233B2/en not_active Expired - Fee Related
- 2008-06-13 KR KR1020107000650A patent/KR20100038098A/ko not_active Withdrawn
- 2008-06-13 JP JP2010512198A patent/JP2010529197A/ja not_active Abandoned
- 2008-06-13 CN CN2008800201249A patent/CN101707877B/zh not_active Expired - Fee Related
2009
- 2009-12-10 IL IL202685A patent/IL202685A0/en unknown
- 2009-12-10 ZA ZA2009/08828A patent/ZA200908828B/en unknown
2013
- 2013-06-28 US US13/930,838 patent/US20130344184A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20130344184A1 (en)	2013-12-26
CA2691132A1 (en)	2008-12-24
KR20100038098A (ko)	2010-04-12
CN101707877B (zh)	2013-01-09
BRPI0812729A2 (pt)	2019-02-12
EP2392321A1 (de)	2011-12-07
NZ581710A (en)	2012-02-24
EP2162125B1 (de)	2011-10-19
WO2008156671A3 (en)	2009-03-12
CN101707877A (zh)	2010-05-12
US8476233B2 (en)	2013-07-02
IL202685A0 (en)	2010-06-30
JP2010529197A (ja)	2010-08-26
ZA200908828B (en)	2010-12-29
EP2162125A4 (de)	2010-08-25
MX2009013683A (es)	2010-04-07
AU2008266996A1 (en)	2008-12-24
CA2691132C (en)	2016-01-12
WO2008156671A2 (en)	2008-12-24
EP2162125A2 (de)	2010-03-17
US20100184728A1 (en)	2010-07-22

Legal Events

Date	Code	Title	Description
2012-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE529105T1 (de)	2011-11-15	Zusammensetzung zur rektalen verabreichung kombiniert mit einer oralen zusammentzung enthaltend alpha liponsäure zur behandlung von entzündlicher darmerkrankung
Martinez-Arguelles et al.	2009	In utero exposure to di-(2-ethylhexyl) phthalate decreases mineralocorticoid receptor expression in the adult testis
Jokstad et al.	1996	Ten years' clinical evaluation of three luting cements
Patel et al.	2016	Molar incisor hypomineralization
MA28935B1 (fr)	2007-10-01	Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
WO2008085484A3 (en)	2008-09-18	Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
AR079479A1 (es)	2012-01-25	Composiciones oftalmicas no irritantes de povidona iodada
BRPI0512535A (pt)	2008-03-25	compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
EA201270666A1 (ru)	2012-12-28	Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EP2331095A4 (de)	2012-03-21	Bestimmte kynurenin-3-monooxygenase-inhibitoren, pharmazeutische zusammensetzungen und anwendungsverfahren dafür
UA110463C2 (ru)	2016-01-12	ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
DE602004028731D1 (de)	2010-09-30	Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
NO20076405L (no)	2008-02-11	Anvendelse av 24-nor-UDCA
EP3914242A4 (de)	2023-02-01	Zusammensetzungen und verfahren zur diagnose und behandlung von störungen im zusammenhang mit der qualität des alterns und der langlebigkeit
EP4371573A4 (de)	2025-08-20	Medizinische zusammensetzung zur behandlung von entzündlicher darmerkrankung
ZA202002103B (en)	2023-12-20	Compounds as mpges-1 inhibitors
AR058749A1 (es)	2008-02-20	Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento
Chirca et al.	2015	The prevalence of caries in first permanent molar in a group of school children aged 6 to 7 years in pitești
Kang et al.	2018	Changing etiology in liver cirrhosis in Sapporo, Japan
Liu et al.	2013	Prevalence of developmental maxillary midline diastema in Taiwanese children
EP2231148A4 (de)	2011-04-27	Pharmazeutische Zusammensetzung zur Behandlung und Vorbeugung von Herzerkrankungen
ATE549923T1 (de)	2012-04-15	Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer
BR112015005297A2 (pt)	2017-07-04	composição para limpeza dental
BR112017025392A2 (pt)	2018-08-07	composições vaginais dependentes de ph e métodos de tratamento de distúrbios vaginais
ATE494891T1 (de)	2011-01-15	Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung